Fig. 4: Systemic antitumor effect is specific for whole-cell tumor antigens.
From: Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
a Treatment scheme. Mice (n = 10 per group) were inoculated in the left flank with B16F10 cells, E0771 cells, or PBS on day 0. After 4 days, B16F10 cells were implanted into the right flank. The mice were treated with intratumoral injections of 35 nmol α-melittin-NPs (quantification was based on the peptide content) in PBS, with a total volume of 50 μl, on days 7 and 9. b Growth of tumors in the right flank. c Individual tumor growth kinetics of the right tumors. Data are shown as the mean ± SEM. **P < 0.01 and ****P < 0.0001, as analyzed by one-way ANOVA with Bonferroni’s post hoc test (b). Source data are provided as a Source Data file.
